Please assess the completion status of the following clinical trial:

Trial Title: Lymphatic Filariasis (LF) in Ivory Coast

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women and men 18-70 years~* ≥50 MF/mL based on Nuclepore filtration~* Willing to give informed consent~Exclusion Criteria:~* Prior treatment for LF within last 5 years~* Pregnancy (perform pregnancy test)~* Hemoglobin \<7 g/dL~* Permanent disability, serious medical illness that prevents or impedes study participation and/or comprehension~* AST/ALT and creatinine \>1.5 upper limit of normal~* Proteinuria or hematuria \>3+~* Skin snip positivity for O. volvulus MF

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Standard Treatment (Type: ACTIVE_COMPARATOR): Albendazole 400 mg + Ivermectin 200 µg/kg body weight administered annually (at 0, 12 and 24 months)
- ALB 400 mg x2 per year (Type: EXPERIMENTAL): Albendazole 400 mg given at 0, 6, 12, 18, 24 and 30 months
- ALB 800 mg x2 per year (Type: EXPERIMENTAL): Albendazole 800 mg given at 0, 6, 12, 18, 24 and 30 months
- ALB 400mg + IVM 200mcg/kg + DEC 6mg/kg (Type: EXPERIMENTAL): Albendazole 400 mg plus Ivermectin 200 µg/kg body weight plus Diethylcarbamazine 6 mg/kg body weight given one time only

Based on this trial design, predict the completion outcome and termination type (if applicable).